Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.
For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).
Se habla español.
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Clinical Trial for Chronic Lymphocytic Leukemia (CLL)
The research study sets out to learn about changes in the genetic makeup of CLL during the early phase of treatment with venetoclax. The initial phase of venetoclax therapy can be medically and logistically challenging. Patients will receive expert medical care at the National Institutes of Health (NIH).
Partner in Research
The NIH is looking for patients with CLL that has progressed despite treatment or were intolerant to therapy.
Treatment at NIH
Patients are provided the novel agent venetoclax for roughly five weeks. There is no charge for study-related tests, procedures or medications at NIH. Patients have NIH follow-up every six months. Compensation for travel and lodging is provided.
Continue at Local Providers
After the initial phase of venetoclax is complete, patients transition to the care of their local hematologist/oncologist to receive venetoclax through their provider.
Location: The NIH Clinical Center, America's Research Hospital, is located in Bethesda, Maryland, on the Metro red line (Medical Center stop). Parking is available.
For more information:
NIH Clinical Center Office of Patient Recruitment
1-800-411-1222 (refer to study # 19-H-0111)
(TTY users call via MD Relay 7-1-1)
Se habla español
Or go online:
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 02/25/2020